Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ \ Origin:\ Appendix\ 5\ \ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12,\ 04/03/13,\ 01/08/12,\ 01/08/1$ 

Name of entity	
CCP Technologies Limited	

ABN

58 009 213 754

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 \*Class of \*securities issued or to be issued
- (a) Unlisted options
- (b) Share Rights
- Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- (a) 1,446,550
- (b) 10,000,000
- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- (a) Unlisted options with exercise price of \$0.10 per option, expiring 20 November 2021
- (b) Share Rights expiring 31 December 2020. Other terms of these securities can be found on the Notice of AGM lodged with ASX on 5 October 2017

<sup>+</sup> See chapter 19 for defined terms.

4 Do the +securities rank equally in (a) & (b) Upon the exercise of these securities, all respects from the +issue date the ordinary shares received by holders will with an existing +class of quoted rank equally with existing quoted shares on +securities? **ASX** If the additional +securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration (a) & (b) Nil Purpose of the issue (a) Issue in lieu of director fees 6 (If issued as consideration for the acquisition of assets, clearly (b) Issue as long term incentives as part of the identify those assets) Executive Directors employment contract 6a Is the entity an +eligible entity that | No has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder N/A resolution under rule 7.1A was passed Number of +securities issued 6c N/A without security holder approval under rule 7.1 Number of \*securities issued with N/A 6d security holder approval under rule 7.1A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	(a) 1,446,550 (b) 10,000,000	
		<u></u>	<u></u>
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
бі	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	See below	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	21 November 2017	
	Cross reference: item 33 of Appendix 3B.		
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	Number 213,627,332	+Class Fully paid ordinary shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (*including* the +securities in section 2 if applicable)

Number	+Class
71,783,786	Restricted ordinary
	shares (escrowed
	until 15 September
	2018)
30,000,000	Milestone Shares
	capable of converting
	to 6,000,000 ordinary
	shares on
	achievement of
	milestone targets
4,000,000	Unlisted options
	vesting on 15
	December 2018 and
	expiring on 15
	December 2020 with
	an exercise price of
1 722 000	\$0.10 per option
1,533,000	Unlisted options
	vesting on 15
	December 2017 and
	expiring on 15
	December 2019 with
	an exercise price of
1 446 550	\$nil per option Unlisted options
1,446,550	1
	0
	expiring on 20 November 2021 with
	an exercise price of
	\$0.10 per option
10,000,000	Share Rights vesting
10,000,000	on 31 December 2019
	expiring on 31
	December 2020 with
	an exercise price of
	\$0.10 per right

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

#### Part 2 - Pro rata issue

11 Is security holder approval required?

N/A			

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of	N/A
20	acceptances or renunciations Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	their	do security holders dispose of entitlements (except by sale th a broker)?	N/A	
33	<sup>+</sup> Issue	date	N/A	
	•	uotation of securitie omplete this section if you are appl		
34	Type of	of <sup>+</sup> securities <i>ne</i> )		
(a)		+Securities described in Part 1		
(b)		=	of the escrowed period, partly paid securities that become fully paid, employee nds, securities issued on expiry or conversion of convertible securities	
Entities that have ticked box 34(a)				
Additi	onal s	ecurities forming a new cla	ass of securities	
Tick to docume		you are providing the informat	ion or	
35		- ·	securities, the names of the 20 largest holders of the number and percentage of additional *securities held by	
36			y securities, a distribution schedule of the additional ber of holders in the categories	
37		A copy of any trust deed for th	e additional <sup>+</sup> securities	

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A	
40	Do the <sup>+</sup> securities rank equally in all respects from the <sup>+</sup> issue date with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?	N/A	
	If the additional *securities do not rank equally, please state:  • the date from which they do		
	<ul> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not</li> </ul>		
	rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and taless of all targets	Number	+Class
42	Number and *class of all *securities quoted on ASX ( <i>including</i> the *securities in clause 38)	N/A	N/A

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

-

Sign here: Date: 21 November 2017

Company secretary

Print name: Phillip Hains

<sup>+</sup> See chapter 19 for defined terms.

== == == == ==

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	202,755,158	
<ul> <li>Add the following:         <ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> </ul> </li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate</li> </ul> </li> </ul>	82,655,960	
line items  Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-	
"A"	285,411,118	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	42,811,668	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
<b>Insert</b> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	-	
• Under an exception in rule 7.2		
• Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	-	
Step 4: Subtract "C" from ["A" x "l placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	42,811,668	
Note: number must be same as shown in Step 2		
Subtract "C"	-	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.15] – "C"	42,811,668	
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	285,411,118	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	28,541,112	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of <sup>+</sup> equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	-	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	-	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	28,541,112	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	28,541,112	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.